VRTX · NASDAQ · STOCK
Vertex Pharmaceuticals (VRTX) Stock Analysis
$510.15
52W $402.58 – $560.25
65/100
$129.46B
29.5
0.32
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is VRTX Bullish or Bearish?
Bullish.
Innellis AI committee rates Vertex Pharmaceuticals (VRTX) Buy with a composite score of 65/100
, based on 6 analysts with 67% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +9.93 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -10.07 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Risk Analyst sees a compelling case — low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- ROE of 23.3% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock — Risk
- News sentiment is positive (+0.33 across 33 articles, 14d) — News
Bear Case
- P/E of 29.0 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
65/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 4%
of 192 Healthcare peers
Value Analyst
neutral
54
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 23.3% shows genuine earnings power backing the valuation
− P/E of 29.0 is moderate-to-rich
Growth Analyst
bullish
75
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst
bullish
80
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
68
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.33 across 33 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 65.1 to 65.1.
- New bearish signals: 1 appeared.
- Bullish support removed: 1 signal(s) disappeared.
- New bullish signals: 1 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
Analyst-level changes:
- News Analyst: +1 bullish signal(s).
- Value Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
47.1
Neutral
MACD Histogram
-1.349
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Support
$466.76
Resistance
$510.59
Bollinger %B
0.39
Inside Bands
Price vs Moving Averages
EMA 9
$509.15
Above
EMA 21
$514.36
Below
EMA 50
$512.76
Below
EMA 200
$481.21
Above
Fundamental Analysis
Valuation
50
Growth
55
Profitability
100
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
29.5×
P/B Ratio
6.40×
PEG Ratio
1.31
Dividend Yield
0.00%
52W High
$560.25
52W Low
$402.58
Quality & Growth
ROE
2117.9%
ROA
1512.2%
Gross Margin
8603.6%
Operating Margin
3859.2%
Revenue Growth YoY
—
Debt / Equity
0.10
AI Fundamental Assessment
P/E ratio of 29.5 (moderate relative to a 15-40x range); Price-to-book of 6.4x; PEG ratio of 1.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 21.2%; Return on assets of 15.1%; Net margin of 34.9%; Gross margin of 86.0%; Current ratio of 3.19 (healthy short-term liquidity); Debt-to-equity of 0.10; Free cash flow per share is positive (14.95); Most recent quarter missed estimates by 2.1%; EPS growth accelerating (-11.1% -> +5.8% QoQ); Average YoY EPS growth of 4.7%; Analyst estimates falling over recent quarters
Get the Full VRTX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →